Last reviewed · How we verify

Dr.dr.Irma Bernadette, SpKK (K) — Portfolio Competitive Intelligence Brief

Dr.dr.Irma Bernadette, SpKK (K) pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Cleanser Cleanser marketed Other
spot cream spot cream marketed Dermatology
Adapalene 0,1% cream Adapalene 0,1% cream phase 3 Retinoid Retinoic acid receptor gamma (RARγ) Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Army Medical University, China · 1 shared drug class
  3. Bausch Health Americas, Inc. · 1 shared drug class
  4. Center for Sight Las Vegas · 1 shared drug class
  5. Centro Dermatológico Dr. Ladislao de la Pascua · 1 shared drug class
  6. Cipher Pharmaceuticals Inc. · 1 shared drug class
  7. Dr. Emmy Graber · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dr.dr.Irma Bernadette, SpKK (K):

Cite this brief

Drug Landscape (2026). Dr.dr.Irma Bernadette, SpKK (K) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-dr-irma-bernadette-spkk-k. Accessed 2026-05-16.

Related